Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MKenneth S. Thress, Geoffrey R. Oxnard, Dalia Ercan et al.|Nature Medicine|2015Cited by 1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung CancerGeoffrey R. Oxnard, Pasi A. Jänne, Kenneth S. Thress et al.|Journal of Clinical Oncology|2016Cited by 843
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Cristina Cruz et al.|EMBO Molecular Medicine|2018Cited by 271
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDanish Memon, Matthew D. Hellmann, Adam J. Schoenfeld et al.|Cancer Cell|2024Cited by 177